iX Biopharma (SGX:42C
) announced on July 14 that it has allotted and issued 2,915,442 new ordinary shares, following the exercise of warrants, at an exercise price of 6 cents per share.
Out of the 2,915,442 new ordinary shares, 1,004,036 new ordinary shares are allotted and issued to Albert Ho Shing Tung, who is the company’s non-executive non-independent director and 15,301 new ordinary shares to Centrum Capital Pte Ltd, a company in which Ho has a deemed interest.
As a result of this latest exercise of warrants, iX Biopharma’s total number of issued shares has increased from 1,074,528,272 shares to 1,077,443,714 shares.
The new ordinary shares rank pari passu in all respects with the existing shares and are expected to be listed and quoted on SGX-ST on or around July 16.
As of this latest announcement, 41,266,650 warrants have been exercised, which represent 71.76% of all warrants previously issued and there are still 16,242,829 outstanding warrants left and will expire on July 17 at 5pm.
Shares of iX Biopharma closed 1 cent higher, or 2.78% up at 37 cents on July 14.
